Compare Aon PLC (AON) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aon PLC vs ResMed Inc. — how do they compare? Aon PLC trades at $357.49 (market cap $76.23B), while ResMed Inc. trades at $198.79 (market cap $29.57B). The key difference: Aon PLC is far larger — about 2.6× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.18%). Which is the better fit depends on your goals.
| AON | RMD | |
|---|---|---|
Market Cap | $76.23B | $29.57B |
Sector | Financials | Health |
52-Week High | $375.27 | $293.73 |
52-Week Low | $308.22 | $182.82 |
Enterprise Value | $90.29B | $28.76B |
Dividend Yield | 0.92% | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AON trades at $356.94, up 0.39% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q1 2026 EPS of $6.48 beating expectations and revenue growth from $17.18B in 2025 to projected $17.5B in 2026. Net income margin improved to 22.54% with robust ROE of 46.82%. Recent news highlights dividend declarations and upcoming Q2 earnings.
AON presents a compelling investment case with consistent earnings beats, strong profitability metrics, and analyst consensus target of $399.67 offering 12% upside. Risks include elevated valuation multiples and debt levels, while institutional sentiment remains positive with 50% buy ratings. The stock's technical strength and fundamental growth support continued upward momentum.
ResMed (RMD) trades at $203.87, down 2.2% today, but maintains strong fundamentals with consistent earnings beats and robust profitability. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show a bullish trend with support at $202, while fundamentals reveal impressive 27.4% net margins and steady revenue growth from $5.15B in 2025 to projected $5.5B in 2026.
RMD presents a compelling investment case with 28% upside to analyst consensus target of $254.57, supported by strong cash flow generation and strategic business optimization. Key risks include competitive pressures in the sleep apnea market and potential market share challenges from new pharmaceutical treatments. The balanced analyst coverage (15 Buy, 15 Hold, 5 Sell) suggests cautious optimism amid the company's solid execution and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aon PLC
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
